Analyst update from H.C. Wainwright and the FDA's breakthrough designation for umbralisib gives TGTX shareholders some hope.TG Therapeutics analyst commentary at H.C. WainwrightH.C. Wainwright keeps Buy on TG Therapeutics after breakthrough designation. After TG Therapeutics announced that umbralisib received FDA Breakthrough Therapy Designation in the treatment of adult marginal zone lymphoma patients, H.C. Wainwright analyst Edward White noted that he estimates umbralisib will be launched in the non-Hodgkin's lymphoma indication in 2021. White, who continues to view U2 therapy as a potential base for triplet or quad combination therapy in NHL patients, keeps a Buy rating and $20 price target on TG Therapeutics shares.Read more at: (source)https://thefly.com/landingPage...TG Therapeutics announces breakthrough therapy designation for umbralisibTG Therapeutics announced that the FDA has granted breakthrough therapy designation for umbralisib for the treatment of adult patients with marginal zone lymphoma, or MZL, who have received at least one prior anti-CD20 regimen. There are currently no fully approved agents for MZL. The breakthrough therapy designation was based on interim data from the MZL cohort evaluating umbralisib monotherapy in the ongoing UNITY-NHL Phase 2b registration-directed clinical trial.Read more at: (source)https://thefly.com/landingPage...* This stock has been on our trading list for a while now. Will continue to look for trades in this name. * Tiger's Take: "A good long term spec play in the medical field that has already been beaten down. I do see potential here longer-term." $TGTX, TG Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.